News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Mesoblast.
RELATED STOCKHEAD STORIES
News
ASX stocks in America: Opthea’s about to join the ranks but who’s there already?
Health & Biotech
Mesoblast has treated dozens of COVID-19 patients with its remestemcel-L drug
News
Hot Money Monday: These are the most in-demand stocks on the ASX right now
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX Small Cap Lunch Wrap: Wake me up when September ends
Health & Biotech
Mesoblast plunges after US FDA requires new trial
News
10 at 10: These ASX stocks are riding like the wind this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Mesoblast now expects to release Ryoncil ruling on Monday
Health & Biotech
Crucial period for Mesoblast as key FDA ruling looms
Health & Biotech
Cynata stem cell technology a triumph: scientist
Health & Biotech
Mesoblast’s potential Covid-19 treatment wins industry award
Experts
ScoPo’s health powerplays: Pot stocks get a boost
Experts
Scopo’s Health Powerplays: Show me the (grant) money
Health & Biotech
Check up: Health sector slips as earning season ends
Health & Biotech
